Literature DB >> 7915305

A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency.

E Jacquemin1, K D Setchell, N C O'Connell, A Estrada, G Maggiore, J Schmitz, M Hadchouel, O Bernard.   

Abstract

There have been a few reports of infants with severe neonatal cholestasis related to a defect in primary bile acid synthesis. To assess the importance of such deficiency among children with progressive intrahepatic cholestasis (Byler disease), screening for inborn errors in bile acid synthesis was performed by fast atom bombardment ionization-mass spectrometry of urine samples from 30 affected children. Bile acid analysis revealed a specific fast atom bombardment ionization-mass spectrometry profile for 3 beta-hydroxy-C27 steroid dehydrogenase/isomerase deficiency in five children who had jaundice, hepatosplenomegaly, and fatty stools beginning at ages ranging from 4 to 46 months. None of them had pruritus. Liver function tests showed persistently normal serum gamma-glutamyltransferase activity, low serum cholesterol and vitamin E levels, normal serum bile acid concentrations despite raised serum bilirubin levels, and decreased prothrombin time and clotting factor V. In four of the cases a similar disease was observed in siblings. Liver function returned to normal after oral ursodeoxycholic acid therapy. We conclude that 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency should be considered when idiopathic cholestatic liver disease with clinical features akin to Byler disease is characterized by the association of normal serum gamma-glutamyltransferase activity, normal serum bile acid concentration, absence of pruritus, and a return to normal liver function during ursodeoxycholic acid therapy. Early identification of these children is essential because they benefit from bile acid therapy and might thus avoid the need for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915305     DOI: 10.1016/s0022-3476(05)83280-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

Review 1.  The molecular genetics of familial intrahepatic cholestasis.

Authors:  P L Jansen; M Müller
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  Locus heterogeneity in progressive familial intrahepatic cholestasis.

Authors:  S S Strautnieks; A F Kagalwalla; M S Tanner; R M Gardiner; R J Thompson
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

3.  An inborn error of bile acid synthesis (3beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency) presenting as malabsorption leading to rickets.

Authors:  A K Akobeng; P T Clayton; V Miller; M Super; A G Thomas
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

4.  Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis.

Authors:  Cong Liu; Bruce J Aronow; Anil G Jegga; Ning Wang; Alex Miethke; Reena Mourya; Jorge A Bezerra
Journal:  Gastroenterology       Date:  2006-10-21       Impact factor: 22.682

5.  Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.

Authors:  J M de Vree; E Jacquemin; E Sturm; D Cresteil; P J Bosma; J Aten; J F Deleuze; M Desrochers; M Burdelski; O Bernard; R P Oude Elferink; M Hadchouel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

6.  Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.

Authors:  P T Clayton; K A Mills; A W Johnson; A Barabino; M G Marazzi
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

Review 7.  Bile acids: chemistry, physiology, and pathophysiology.

Authors:  Maria J Monte; Jose J G Marin; Alvaro Antelo; Jose Vazquez-Tato
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 8.  Mechanisms of disease: Inborn errors of bile acid synthesis.

Authors:  Shikha S Sundaram; Kevin E Bove; Mark A Lovell; Ronald J Sokol
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-06-24

Review 9.  New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients.

Authors:  Dominique Debray; Nadya Yousef; Philippe Durand
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

10.  Anaesthetic considerations in progressive familial intrahepatic cholestasis (Byler's disease).

Authors:  G Müller; F Veyckemans; M Calier; L J Van Obbergh; M De Kock; E M Sokal; J B Otte
Journal:  Can J Anaesth       Date:  1995-12       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.